1. Home
  2. PDSB vs ICCC Comparison

PDSB vs ICCC Comparison

Compare PDSB & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PDSB
  • ICCC
  • Stock Information
  • Founded
  • PDSB 2005
  • ICCC 1982
  • Country
  • PDSB United States
  • ICCC United States
  • Employees
  • PDSB N/A
  • ICCC N/A
  • Industry
  • PDSB Biotechnology: Pharmaceutical Preparations
  • ICCC Biotechnology: Pharmaceutical Preparations
  • Sector
  • PDSB Health Care
  • ICCC Health Care
  • Exchange
  • PDSB Nasdaq
  • ICCC Nasdaq
  • Market Cap
  • PDSB 72.2M
  • ICCC 60.1M
  • IPO Year
  • PDSB N/A
  • ICCC 1987
  • Fundamental
  • Price
  • PDSB $1.35
  • ICCC $6.71
  • Analyst Decision
  • PDSB Strong Buy
  • ICCC
  • Analyst Count
  • PDSB 2
  • ICCC 0
  • Target Price
  • PDSB $10.00
  • ICCC N/A
  • AVG Volume (30 Days)
  • PDSB 516.6K
  • ICCC 41.8K
  • Earning Date
  • PDSB 08-12-2025
  • ICCC 08-12-2025
  • Dividend Yield
  • PDSB N/A
  • ICCC N/A
  • EPS Growth
  • PDSB N/A
  • ICCC N/A
  • EPS
  • PDSB N/A
  • ICCC N/A
  • Revenue
  • PDSB N/A
  • ICCC $27,302,766.00
  • Revenue This Year
  • PDSB N/A
  • ICCC N/A
  • Revenue Next Year
  • PDSB N/A
  • ICCC N/A
  • P/E Ratio
  • PDSB N/A
  • ICCC N/A
  • Revenue Growth
  • PDSB N/A
  • ICCC 28.29
  • 52 Week Low
  • PDSB $0.85
  • ICCC $3.34
  • 52 Week High
  • PDSB $4.42
  • ICCC $7.60
  • Technical
  • Relative Strength Index (RSI)
  • PDSB 41.32
  • ICCC 49.68
  • Support Level
  • PDSB $1.18
  • ICCC $5.63
  • Resistance Level
  • PDSB $1.66
  • ICCC $7.14
  • Average True Range (ATR)
  • PDSB 0.11
  • ICCC 0.64
  • MACD
  • PDSB -0.05
  • ICCC -0.06
  • Stochastic Oscillator
  • PDSB 22.42
  • ICCC 42.58

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Share on Social Networks: